Enanta Pharmaceuticals Inc (ENTA)


Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Enanta Pharmaceuticals Inc chart...

About the Company

enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.

CEO

Jay Luly

Exchange

NASDAQ

Website

https://www.enanta.com/

$38M

Total Revenue

158

Employees

$286M

Market Capitalization

-2.06

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ENTA News

Enanta Pharmaceuticals Inc ENTA

5d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

1mon ago, source: Yahoo Finance

The analysts might have been a bit too bullish on Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), given that the company fell short of expectations when it released its quarterly results last week.

Enanta Pharmaceuticals files patent for 17ß-HSD13 inhibitors for treating metabolic disease

6d ago, source: Pharmaceutical Technology

Discover Enanta Pharmaceuticals' groundbreaking patent for Formula (I) compounds as 17ß-HSD13 inhibitors, targeting metabolic diseases and liver conditions. Learn about the potential therapeutic ...

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript

1mon ago, source: Seeking Alpha

Good afternoon and welcome to Enanta Pharmaceuticals' Fiscal First Quarter Financial Results Conference Call. At this time, all participants are on a listen-only mode. There will be a question-and ...

Enanta Pharmaceuticals Inc.

1mon ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

ENTA Enanta Pharmaceuticals, Inc.

7d ago, source: Seeking Alpha

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Enanta Pharmaceuticals Inc.

17d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Enanta Pharmaceuticals Inc

25d ago, source: U.S. News & World Report

A FINRA report shows investors of color are the fastest-growing group in the stock market, and they're coming in at a younger age. Sometimes it makes sense to sell a stock at a loss. Here's how to ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...